Transcriptional changes induced by fulvestrant and anastrozole treatment in ER-positive breast cancers

ABSTRACT: Analysis of breast cancer tumors following fulvestrant treatment for 4 weeks. Fulvestrant is a highly specific ER antagonist used to treat postmenopausal women with breast cancer. Data provide insight into the molecular mechanism of action of fulvestrant on whole genome expression.

ORGANISM(S): Homo sapiens

SUBMITTER: Zara Ghazoui 

PROVIDER: E-MTAB-887 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress